1341-9625
Bimonthly
No
INT J CLIN ONCOL
1996
134
JAPAN
http://www.springer.com/medicine/oncology/journal/10147
平均2月审稿时间
约25%平均录用比例
2.8影响因子
肿瘤学小学科
160/326JIF RANK
5493总被引频次
月期刊平台服务过的文章录用时间为1-3个月,依据20年经验,经月期刊专家预审通过后的文章,投稿通过率100%以上!
《国际临床肿瘤学杂志》(IJCO)欢迎关于临床肿瘤学各个方面的原始研究论文,这些论文报告了新的和及时的研究结果。鼓励进行临床试验报告。如果实验研究与临床肿瘤学有明显的相关性,也将被接受。日本临床肿瘤学学会的会员资格不是提交该杂志的先决条件。收到论文的前提是:其内容未全部或部分在其他地方出版;至少有两名裁判员和编辑对其进行同行评审,并对其语言和内容进行编辑性修改;编辑对其接受、拒绝和出版顺序负责。
https://mc.manuscriptcentral.com/ijco?PROXY_TO_PAGE_NAME=&PRE_ACTION=&DISPLAY=&CURRENT_PAGE=LOGIN&SAVE_MS_DETAILS_VALIDATE_FL=&SAVE_MS_DETAILS_FL=&NEX
The International Journal of Clinical Oncology (IJCO) welcomes original research papers on all aspects of clinical oncology that report the results of novel and timely investigations. Reports on clinical trials are encouraged. Experimental studies will also be accepted if they have obvious relevance to clinical oncology. Membership in the Japan Society of Clinical Oncology is not a prerequisite for submission to the journal. Papers are received on the understanding that: their contents have not been published in whole or in part elsewhere; that they are subject to peer review by at least two referees and the Editors, and to editorial revision of the language and contents; and that the Editors are responsible for their acceptance, rejection, and order of publication.